InvestorsHub Logo
Followers 828
Posts 119324
Boards Moderated 16
Alias Born 09/05/2002

Re: tony111 post# 14416

Wednesday, 08/26/2015 10:19:38 AM

Wednesday, August 26, 2015 10:19:38 AM

Post# of 20689
Teva’s three 40mg Copaxone patents in the Orange Book (8232250, 8399413, 8969302) are method-of-use patents, which are generally easier to invalidate than composition-of-matter patents.

Yesterday’s USPTO news (#msg-116493514) concerns the first two of the three aforementioned patents, and a USPTO preliminary ruling on an IPR for the third patent is expected soon.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”